Preventive Effects Of Cardotoxicities By Liposomal Anthracyclines Non Pegilated In 95 Perspective Patients Affected By Lymphoma And Monitored By Biomarkers And Ecocardiography

Anthracyclines (AC) still constitute the mainstay of the 1st line treatment in lymphoma: their use, however, is limited by the occurrence of Cardiac Toxicity (CT). The exact prevalence of AC CT occurring after widely used regimens such as R-CHOP or ABVD is unknown and there is uncertainty about the best monitoring method and possible prophylactic or therapeutic interventions.